BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9407961)

  • 1. Aggressive breast cancer leads to discrepant serum levels of the type I procollagen propeptides PINP and PICP.
    Jukkola A; Tähtelä R; Thölix E; Vuorinen K; Blanco G; Risteli L; Risteli J
    Cancer Res; 1997 Dec; 57(24):5517-20. PubMed ID: 9407961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer.
    Tähtelä R; Thölix E
    Anticancer Res; 1996; 16(4B):2289-93. PubMed ID: 8694558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
    Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
    Kobayashi Y; Ochi M; Tokue A
    Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative PINP in serum reflects metastatic potential and poor survival in node-positive breast cancer.
    Jukkola A; Bloigu R; Holli K; Joensuu H; Valavaara R; Risteli J; Blanco G
    Anticancer Res; 2001; 21(4B):2873-6. PubMed ID: 11712779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases.
    Francini G; Gonnelli S; Petrioli R; Bruni S; Marsili S; Aquino A; Camporeale A
    Cancer Epidemiol Biomarkers Prev; 1993; 2(2):125-9. PubMed ID: 8467247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative high type I collagen degradation marker ICTP reflects advanced breast cancer.
    Keskikuru R; Kataja V; Kosma VM; Eskelinen M; Uusitupa M; Johansson R; Risteli L; Risteli J; Jukkola A
    Anticancer Res; 1999; 19(5C):4481-4. PubMed ID: 10650796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical usefulness of blood PICP, PINP and ICTP concentrations as bone metastasis markers in prostate cancer patients].
    Kobayashi Y; Tokue A
    Nihon Rinsho; 1998 Aug; 56(8):2072-6. PubMed ID: 9750510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of total and intact aminoterminal propeptide of type I procollagen assays in patients with breast cancer with or without bone metastases.
    Marin L; Koivula MK; Jukkola-Vuorinen A; Leino A; Risteli J
    Ann Clin Biochem; 2011 Sep; 48(Pt 5):447-51. PubMed ID: 21733929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Correlation of procollagen (I) with prostate specific antigen and bone scan for the diagnosis of bone metastases in patients with prostate carcinoma].
    Zissimopoulos A; Stellos C; Petrakis G; Baziotis N
    Hell J Nucl Med; 2004; 7(3):162-7. PubMed ID: 15841291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Detection of serum PICP and PINP and COL1alpha1 DNA sequence analysis in patients with arsenic poisoning in Dazhuyuan Town, Ankang area in southern Shaanxi Province].
    Wang ZF; Guo X; Bai GL; Wang LX; Lei YX
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jul; 28(7):1141-4. PubMed ID: 18676246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer.
    Koizumi M; Yonese J; Fukui I; Ogata E
    J Urol; 2002 Apr; 167(4):1863-6. PubMed ID: 11912449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin D supplementation to healthy children does not affect serum osteocalcin or markers of type I collagen turnover.
    Schou AJ; Heuck C; Wolthers OD
    Acta Paediatr; 2003 Jul; 92(7):797-801. PubMed ID: 12892157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discrepant expression of carboxy- and aminoterminal propeptides of type I procollagen predicts poor clinical outcome in epithelial ovarian cancer.
    Simojoki M; Santala M; Risteli J; Kauppila A
    Gynecol Oncol; 2003 Mar; 88(3):358-62. PubMed ID: 12648587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum type I collagen degradation markers, ICTP and CrossLaps, are factors for poor survival in lung cancer.
    Ylisirniö S; Sassi ML; Risteli J; Turpeenniemi-Hujanen T; Jukkola A
    Anticancer Res; 1999; 19(6C):5577-81. PubMed ID: 10697621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type I collagen metabolites as tumor markers in patients with lung carcinoma.
    Kobayashi T; Gabazza EC; Taguchi O; Risteli J; Risteli L; Kobayashi H; Yasui H; Yuda H; Sakai T; Kaneda M; Adachi Y
    Cancer; 1999 May; 85(9):1951-7. PubMed ID: 10223235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunocytochemical evidence on the effects of glucocorticoids on type I collagen synthesis in human osteoblastic cells.
    Hernández MV; Guañabens N; Alvarez L; Monegal A; Peris P; Riba J; Ercilla G; Martínez de Osaba MJ; Muñoz-Gómez J
    Calcif Tissue Int; 2004 Mar; 74(3):284-93. PubMed ID: 14583839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
    Noguchi M; Noda S
    J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bone and bone related biochemical examinations. Bone and collagen related metabolites. Measurement of PICP and PINP in the evaluation of pharmaceutical treatment efficacy for osteoporosis].
    Nakatsuka K; Nishizawa Y; Miura M
    Clin Calcium; 2006 Jun; 16(6):977-85. PubMed ID: 16751694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PINP as serum marker of metastatic spread to the bone in breast cancer patients.
    Lüftner D; Jozereau D; Schildhauer S; Geppert R; Müller C; Fiolka G; Wernecke KD; Possinger K
    Anticancer Res; 2005; 25(3A):1491-9. PubMed ID: 16033050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.